<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">jofin</journal-id><journal-title-group><journal-title xml:lang="ru">Журнал инфектологии</journal-title><trans-title-group xml:lang="en"><trans-title>Journal Infectology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2072-6732</issn><publisher><publisher-name>IPO “АIDSSPbR"</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.22625/2072-6732-2026-18-2-160-166</article-id><article-id custom-type="elpub" pub-id-type="custom">jofin-2001</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЙ СЛУЧАЙ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINICAL CASE</subject></subj-group></article-categories><title-group><article-title>Гепатоцеллюлярная карцинома у пациентов с хроническим гепатитом с после достижения устойчивого вирусологического ответа: клинические случаи</article-title><trans-title-group xml:lang="en"><trans-title>Hepatocellular Carcinoma in Patients with Chronic Hepatitis C After Achieving Sustained Virological Response: Case Reports</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Новак</surname><given-names>К. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Novak</surname><given-names>K. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Новак Ксения Егоровна – доцент кафедры инфекционных болезней взрослых и эпидемиологии Санкт-Петербургского ГПМУ, к.м.н.</p><p>Санкт-Петербург; тел.: 8(812)277-78-23</p></bio><bio xml:lang="en"><p>Saint-Petersburg</p></bio><email xlink:type="simple">kseniya.novak@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сарыглар</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Saryglar</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Сарыглар Анна Александровна – главный врач Инфекционной больницы Республики Тыва, врач-инфекционист высшей категории, к.м.н.</p><p>Кызыл; тел.: +7-983-593-92-47</p></bio><bio xml:lang="en"><p>Kizil</p></bio><email xlink:type="simple">anna_kyzyl@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Клыс</surname><given-names>У. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Klys</surname><given-names>U. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Клыс Ульяна Евгеньевна – ассистент кафедры инфекционных болезней взрослых и эпидемиологии Санкт-Петербургского ГПМУ, очный аспирант.</p><p>Санкт-Петербург; тел.: 8(812)277-78-23</p></bio><bio xml:lang="en"><p>Saint-Petersburg</p></bio><email xlink:type="simple">ue.kuznetsova@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Монгуш</surname><given-names>М. К.</given-names></name><name name-style="western" xml:lang="en"><surname>Mongush</surname><given-names>M. K.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ондар Сырга Оюн-ооловна – заведующий кабинетом консультативного приема Инфекционной больницы Республики Тыва врач-инфекционист.</p><p>Санкт-Петербург; тел.: +7-952-750-57-53</p></bio><bio xml:lang="en"><p>Kizil</p></bio><email xlink:type="simple">mongush_marianna@list.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ондар</surname><given-names>С. О.</given-names></name><name name-style="western" xml:lang="en"><surname>Ondar</surname><given-names>S. O.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ондар Сырга Оюн-ооловна – заведующий кабинетом консультативного приема Инфекционной больницы Республики Тыва врач-инфекционист.</p><p>Кызыл; тел.: +7-952-750-57-53</p></bio><bio xml:lang="en"><p>Kizil</p></bio><email xlink:type="simple">ajl-k@yandex.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Эсауленко</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Esaulenko</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Эсауленко Елена Владимировна – заведующий кафедрой инфекционных болезней взрослых и эпидемиологии Санкт-Петербургского ГПМУ; заведующий лабораторией «Вирусные гепатиты» Санкт-Петербургского научно-исследовательского института эпидемиологии и микробиологии им. Пастера, д.м.н., профессор.</p><p>Санкт-Петербург; тел.: +7 (812) 277-78-23</p></bio><bio xml:lang="en"><p>Saint-Petersburg</p></bio><email xlink:type="simple">eve-gpmu@mail.ru</email><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Санкт-Петербургский государственный педиатрический медицинский университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Saint-Petersburg State Pediatric Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Инфекционная больница Республики Тыва</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Infectious Hospital of the Republic of Tyva</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Санкт-Петербургский государственный педиатрический медицинский университет; Санкт-Петербургский научно-исследовательский институт эпидемиологии и микробиологии им. Пастера</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Saint-Petersburg State Pediatric Medical University; Saint-Petersburg Institute of Epidemiology and Microbiology named after Pasteur</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2026</year></pub-date><pub-date pub-type="epub"><day>20</day><month>06</month><year>2026</year></pub-date><volume>18</volume><issue>2</issue><fpage>160</fpage><lpage>166</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Новак К.Е., Сарыглар А.А., Клыс У.Е., Монгуш М.К., Ондар С.О., Эсауленко Е.В., 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">Новак К.Е., Сарыглар А.А., Клыс У.Е., Монгуш М.К., Ондар С.О., Эсауленко Е.В.</copyright-holder><copyright-holder xml:lang="en">Novak K.E., Saryglar A.A., Klys U.E., Mongush M.K., Ondar S.O., Esaulenko E.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://journal.niidi.ru/jofin/article/view/2001">https://journal.niidi.ru/jofin/article/view/2001</self-uri><abstract><p>В статье представлены 2 клинических наблюдения, демонстрирующие сохраняющийся риск развития гепатоцеллюлярной карциномы у пациентов с хроническим гепатитом С после достижения устойчивого вирусологического ответа. В первом случае у пациента из Республики Тыва на фоне исходного цирроза печени (F4) после многолетней персистенции вируса и позднего достижения устойчивого вирусологического ответа развилась гепатоцеллюлярная карцинома. Регресс фиброза (F4– F2) и нормальный уровень альфа-фетопротеина способствовали трактовке очаговых образований как аденом, что привело к задержке верификации диагноза на 3 года. Во втором случае у пациента из Санкт-Петербурга с коинфекцией ВИЧ/ВГС гепатоцеллюлярная карцинома выявлена через 1 год после достижения устойчивого вирусологического ответа. Окончательный диагноз (гепатоцеллюлярная карцинома) установлен посмертно при патолого-анатомическом исследовании, тогда как при жизни предполагалась холангиокарцинома. У пациента выявлен опухолевый тромбоз воротной вены, осложнившийся фатальным кровотечением из варикозно расширенных вен пищевода. Представленные наблюдения свидетельствуют о необходимости пожизненного диспансерного наблюдения у пациентов с хроническим гепатитом С, особенно при наличии исходного цирроза и ВИЧ-коинфекции. Любое впервые выявленное гиперваскулярное образование печени у данной категории пациентов необходимо рассматривать как потенциально злокачественное до морфологической верификации.</p></abstract><trans-abstract xml:lang="en"><p>The article presents two clinical observations demonstrating the persistent risk of hepatocellular carcinoma in patients with chronic hepatitis C after achieving sustained virological response. In the first case, a patient from the Republic of Tyva with pre-existing liver cirrhosis (F4) developed hepatocellular carcinoma after long-term virus persistence and late sustained virological response. Fibrosis regression (F4–F2) and normal alpha-fetoprotein levels contributed to the lesions being interpreted as adenomas, leading to a three-year delay in diagnosis verification. In the second case, a patient from St. Petersburg with HIV/HCV coinfection developed hepatocellular carcinoma one year after achieving sustained virological response. The final diagnosis (hepatocellular carcinoma) was established only at autopsy, whereas cholangiocarcinoma had been suspected during life. Portal vein tumor thrombosis was identified, which was complicated by fatal bleeding from esophageal varices. These observations indicate the need for lifelong follow-up in patients with chronic hepatitis C, especially in those with pre-existing cirrhosis and HIV coinfection. Any newly detected hypervascular liver lesion in this patient category should be considered potentially malignant until proven otherwise.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>хронический вирусный гепатит С</kwd><kwd>гепатоцеллюлярная карцинома</kwd><kwd>цирроз печени</kwd><kwd>этиотропная терапия</kwd><kwd>скрининг</kwd><kwd>альфа-фетопротеин</kwd></kwd-group><kwd-group xml:lang="en"><kwd>chronic hepatitis C</kwd><kwd>hepatocellular carcinoma</kwd><kwd>liver cirrhosis</kwd><kwd>antiviral therapy</kwd><kwd>screening</kwd><kwd>alpha-fetoprotein</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263. doi: 10.3322/caac.21834.</mixed-citation><mixed-citation xml:lang="en">Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263. doi: 10.3322/caac.21834.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182-236. doi: 10.1016/j.jhep.2018.03.019.</mixed-citation><mixed-citation xml:lang="en">European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182-236. doi: 10.1016/j.jhep.2018.03.019.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Министерство здравоохранения Российской Федерации. Клинические рекомендации «Рак печени (гепатоцеллюлярный)» [Электронный ресурс]. Москва, 2025. ID: 1_4. Доступно по ссылке: https://oncology-association.ru/wpcontent/uploads/2022/07/rak-pecheni-gepatoczellyulyarnyj.pdf (дата обращения: 19.03.2026).</mixed-citation><mixed-citation xml:lang="en">Ministerstvo zdravookhraneniya Rossiyskoy Federatsii. Klinicheskiye rekomendatsii «Rak pecheni (gepatotsellyulyarnyy)» [Clinical guidelines «Liver cancer (hepatocellular)»] [Internet]. Moscow; 2025. ID: 1_4. Available from: https://oncology-association.ru/wp-content/uploads/2022/07/rakpecheni-gepatoczellyulyarnyj.pdf (accessed: 19.03.2026). (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Kanwal F, Khaderi S, Singal AG, et al. Risk factors for HCC in contemporary cohorts of patients with cirrhosis. Hepatology. 2023;77(3):997-1005. doi: 10.1002/hep.32734.</mixed-citation><mixed-citation xml:lang="en">Kanwal F, Khaderi S, Singal AG, et al. Risk factors for HCC in contemporary cohorts of patients with cirrhosis. Hepatology. 2023;77(3):997-1005. doi: 10.1002/hep.32734.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">International Agency for Research on Cancer. Liver Cancer Fact Sheet. Global Cancer Observatory (GLOBOCAN) 2022 [Internet]. Lyon, France: IARC; 2024 [cited 2026 Mar 19]. Available from: https://gco.iarc.who.int/media/globocan/factsheets/cancers/11-liver-fact-sheet.pdf</mixed-citation><mixed-citation xml:lang="en">International Agency for Research on Cancer. Liver Cancer Fact Sheet. Global Cancer Observatory (GLOBOCAN) 2022 [Internet]. Lyon, France: IARC; 2024 [cited 2026 Mar 19]. Available from: https://gco.iarc.who.int/media/globocan/factsheets/cancers/11-liver-fact-sheet.pdf</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Каприн А.Д., Старинский В.В., Шахзадова А.О., Золотарев Н.Ю., ред. Злокачественные новообразования в России в 2024 году (заболеваемость). Москва: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России; 2025. 178 с.</mixed-citation><mixed-citation xml:lang="en">Kaprin AD, Starinskiy VV, Shakhzadova AO, Zolotarev NYu, editors. Zlokachestvennyye novoobrazovaniya v Rossii v 2024 godu (zabolevayemost) [Malignant neoplasms in Russia in 2024 (incidence)]. Moscow: MNIOI im. P.A. Gertsena – filial FGBU «NMITs radiologii» Minzdrava Rossii; 2025. 178 p. (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Эсауленко Е.В., Лялина Л.В., Останкова Ю.В., и др. Вирусные гепатиты в Российской Федерации / под ред. В.Г. Акимкина, А.А. Тотоляна. – СПб.: ФБУН НИИЭМ имени Пастера, 2024. – 196 с.</mixed-citation><mixed-citation xml:lang="en">Esaulenko E.V., Lyalina L.V., Ostankova Yu.V., et al. Virusnyye gepatity v Rossiyskoy Federatsii [Viral Hepatitis in the Russian Federation] / ed. by V.G. Akimkin, A.A. Totolyan. Saint-Petersburg: Pasteur Institute; 2024. 196 p. (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Новак К.Е., Трифонова Г.Ф., Клыс У.Е., и др. Эпидемиологические характеристики гепатита С: от острых форм до исходов заболевания. Инфекционные болезни. 2024;22(4):15-20.</mixed-citation><mixed-citation xml:lang="en">Novak K.E., Trifonova G.F., Klys U.E., et al. Epidemiologicheskiye kharakteristiki gepatita C: ot ostrykh form do iskhodov zabolevaniya [Epidemiological characteristics of hepatitis C: from acute forms to disease outcomes]. Infektsionnyye bolezni. 2024;22(4):15-20. (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Сарыглар А.А., Донгак С.О., Иброхимова А.Д., и др. Клинико-эпидемиологическая характеристика хронического гепатита С в Республике Тыва. Журнал инфектологии. 2023;15(1):55-60.</mixed-citation><mixed-citation xml:lang="en">Saryglar A.A., Dongak S.O., Ibrokhimova A.D., et al. Kliniko-epidemiologicheskaya kharakteristika khronicheskogo gepatita S v Respublike Tyva [Clinical and epidemiological characteristics of chronic hepatitis C in the Republic of Tyva]. Journal Infectology. 2023;15(1):55-60. (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Эсауленко Е.В., Новак К.Е., Клыс У.Е., и др. Вирусиндуцированная малигнизация печени: эпидемические тенденции и клинический анализ. Инфекционные болезни. 2025;23(3):5-13.</mixed-citation><mixed-citation xml:lang="en">Esaulenko EV, Novak KE, Klys UE, et al. Virus-indutsirovannaya malignizatsiya pecheni: epidemicheskiye tendentsii i klinicheskiy analiz [Virus-induced liver malignancy: epidemiological trends and clinical analysis]. Infektsionnyye bolezni. 2025;23(3):5-13. (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Lv GJ, Ji D, Yu L, et al. Risk of hepatocellular carcinoma occurrence after antiviral therapy for patients with chronic hepatitis C Infection: a systematic review and meta-analysis. Hepatol Int. 2024;18(5):1459-1471. doi: 10.1007/s12072-02410700-7.</mixed-citation><mixed-citation xml:lang="en">Lv GJ, Ji D, Yu L, et al. Risk of hepatocellular carcinoma occurrence after antiviral therapy for patients with chronic hepatitis C Infection: a systematic review and meta-analysis. Hepatol Int. 2024;18(5):1459-1471. doi: 10.1007/s12072-024-10700-7.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Merchante N, Rodríguez-Fernández M, Figueruela M, et al. Impact of HIV on the survival of hepatocellular carcinoma in hepatitis C virus-infected patients. AIDS. 2020;34(10):14971507. doi: 10.1097/QAD.0000000000002578.</mixed-citation><mixed-citation xml:lang="en">Merchante N, Rodríguez-Fernández M, Figueruela M, et al. Impact of HIV on the survival of hepatocellular carcinoma in hepatitis C virus-infected patients. AIDS. 2020;34(10):14971507. doi: 10.1097/QAD.0000000000002578.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Gobran ST, Ancuta P, Shoukry NH. A Tale of Two Viruses: Immunological Insights Into HCV/HIV Coinfection. Front Immunol. 2021;12:726419. doi: 10.3389/fimmu.2021.726419.</mixed-citation><mixed-citation xml:lang="en">Gobran ST, Ancuta P, Shoukry NH. A Tale of Two Viruses: Immunological Insights Into HCV/HIV Coinfection. Front Immunol. 2021;12:726419. doi: 10.3389/fimmu.2021.726419.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Singal AG, Zhang E, Narasimman M, et al. HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: A meta-analysis. J Hepatol. 2022;77(1):128-139. doi: 10.1016/j.jhep.2022.01.028.</mixed-citation><mixed-citation xml:lang="en">Singal AG, Zhang E, Narasimman M, et al. HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: A meta-analysis. J Hepatol. 2022;77(1):128-139. doi: 10.1016/j.jhep.2022.01.028.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Luna-Cuadros MA, Chen HW, Hanif H, et al. Risk of hepatocellular carcinoma after hepatitis C virus cure. World J Gastroenterol. 2022;28(1):96-107. doi: 10.3748/wjg.v28.i1.96.</mixed-citation><mixed-citation xml:lang="en">Luna-Cuadros MA, Chen HW, Hanif H, et al. Risk of hepatocellular carcinoma after hepatitis C virus cure. World J Gastroenterol. 2022;28(1):96-107. doi: 10.3748/wjg.v28.i1.96.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Xu S, Wang J, Liu L, et al. Development and validation of a nomogram for assessing hepatocellular carcinoma risk after SVR in hepatitis C patients with advanced fibrosis and cirrhosis. Infect Agent Cancer. 2024;19(1):17. doi: 10.1186/s13027-02400578-3.</mixed-citation><mixed-citation xml:lang="en">Xu S, Wang J, Liu L, et al. Development and validation of a nomogram for assessing hepatocellular carcinoma risk after SVR in hepatitis C patients with advanced fibrosis and cirrhosis. Infect Agent Cancer. 2024;19(1):17. doi: 10.1186/s13027-02400578-3.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Vutien P, Kim NJ, Moon AM, et al. Hepatocellular carcinoma risk decreases as time accrues following hepatitis C virus eradication. Aliment Pharmacol Ther. 2024;59(3):361-371. doi: 10.1111/apt.17818.</mixed-citation><mixed-citation xml:lang="en">Vutien P, Kim NJ, Moon AM, et al. Hepatocellular carcinoma risk decreases as time accrues following hepatitis C virus eradication. Aliment Pharmacol Ther. 2024;59(3):361-371. doi: 10.1111/apt.17818.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Abdullah AD, Taher HJ, Alareer HSN. Comparing Texture Analysis of Apparent Diffusion Coefficient MRI in Hepatocellular Adenoma and Hepatocellular Carcinoma. Cureus. 2024;16(1):e51443. doi: 10.7759/cureus.51443.</mixed-citation><mixed-citation xml:lang="en">Abdullah AD, Taher HJ, Alareer HSN. Comparing Texture Analysis of Apparent Diffusion Coefficient MRI in Hepatocellular Adenoma and Hepatocellular Carcinoma. Cureus. 2024;16(1):e51443. doi: 10.7759/cureus.51443.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Shi Y, Wang J, Liu X, et al. Female and diabetes are risk factors for alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II negative in hepatocellular carcinoma. Medicine (Baltimore). 2024;103(42):e40100. doi: 10.1097/MD.0000000000040100.</mixed-citation><mixed-citation xml:lang="en">Shi Y, Wang J, Liu X, et al. Female and diabetes are risk factors for alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II negative in hepatocellular carcinoma. Medicine (Baltimore). 2024;103(42):e40100. doi: 10.1097/MD.0000000000040100.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Tian HY, Wang L, Zhang Y, et al. Differential diagnosis of hepatocellular carcinoma and intrahepatic cholangiocarcinoma by ultrasonography combined with multiphase enhanced computed tomography. J Cancer. 2024;15(11):3362-3369. doi: 10.7150/jca.94550.</mixed-citation><mixed-citation xml:lang="en">Tian HY, Wang L, Zhang Y, et al. Differential diagnosis of hepatocellular carcinoma and intrahepatic cholangiocarcinoma by ultrasonography combined with multiphase enhanced computed tomography. J Cancer. 2024;15(11):3362-3369. doi: 10.7150/jca.94550.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
